Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01542411
Recruitment Status : Completed
First Posted : March 2, 2012
Last Update Posted : March 2, 2012
Information provided by (Responsible Party):
Yazd Medical University

Brief Summary:
This study evaluated the effect of anticoagulant treatment on the live-birth rate in women with a history of at least two continuous unexplained miscarriages or thrombophilia. It also compared two methods of treatment with aspirin and aspirin plus heparin.

Condition or disease
Recurrent Pregnancy Loss

Study Type : Observational
Actual Enrollment : 520 participants
Observational Model: Case Control
Time Perspective: Retrospective
Study Start Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

recurrent pregnancy loss
thrombophilia, aspirin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
This project evaluated 520 women with unexplained recurrent miscarriage for four years. They had referred to recurrent abortion clinic of Yazd Reproductive sciences institute. Women with unexplained recurrent miscarriage included in this study

Inclusion Criteria:

  • unexplained recurrent miscarriage,
  • women had previous venous or arterial thromboembolism or who were heterozygous or homozygous for mutations for FV Leiden G1691A, prothrombin gene G20210A (FII G20210A), and methyltetrahydrofolate reductase C677T (MTHFR C677T)

Exclusion Criteria:

  • abnormal karyotypes of both partners,
  • uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy,
  • abnormal ovaries and abnormal endocrine tests.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01542411

Iran, Islamic Republic of
Research and Clinical Centre for Infertility
Yazd, Iran, Islamic Republic of
Sponsors and Collaborators
Yazd Medical University
Principal Investigator: Tahere Jahaninejad, MSC Yazd Shahid Sadoughi Medical Sciences University and Health Services, Yazd, Iran

Responsible Party: Yazd Medical University Identifier: NCT01542411     History of Changes
Other Study ID Numbers: 2362
First Posted: March 2, 2012    Key Record Dates
Last Update Posted: March 2, 2012
Last Verified: February 2012

Additional relevant MeSH terms:
Abortion, Spontaneous
Fetal Death
Abortion, Habitual
Pregnancy Complications
Pathologic Processes
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors